bearish
China Healthcare Weekly (Feb.19) - VBP on Biosimilar Drugs, Poor Performance of Healthcare Sector
229 Views22 Feb 2021 09:28
This article analyzed the new document about VBP for biosimilar drugs, diabetes drugs market, support devices market in interventional fields, disappointing performance in healthcare sector last week.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Healthcare Weekly (Mar.26)28 Mar 2021
- China Healthcare Weekly (Mar.19)21 Mar 2021
- China Healthcare Weekly (Feb.26)01 Mar 2021
- China Healthcare Weekly (Feb.19) - VBP on Biosimilar Drugs, Poor Performance of Healthcare Sector22 Feb 2021
- Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma18 Feb 2021
- Pre-IPO Betta Pharmaceuticals - Insights on Products and Concerns17 Feb 2021
- Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?03 Feb 2021
x